Abstract
Objectives The study was aimed to determine the predominant bacteria causing Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) infection in patients and their antibiotics sensitivity pattern in tertiary care setup.
Methods This descriptive Cross-sectional study was conducted from September 27th 2023 to December 26th 2023 at Shree Birendra Hospital, chhauni, Kathmandu. Sputum samples that were received in the Microbiology laboratory from in patients for routine diagnosis were included in the study. The samples that were received was subjected to gram staining to assess the quality of the sputum sample, and those samples with good quality (mucoid and muco-purulent) was inoculated onto Blood agar, Chocolate agar and Mac Conkey agar for the isolation of the pathogens, and the media was incubated at 37 degrees Celsius overnight. Culture isolates were identified by standard technique(Cowan and Steel’s Manual for the Identification of Medical Bacteria, 1993) and Kirby-Bauer method was used to test antibiotic sensitivity of the pathogenic organisms following protocol of (Clinical and Laboratory Standards Institute, 2018) guidelines.
Results Out of 273 sputum samples, 42/273 (15.4%) showed growth. Five different bacterial species were identified. Among the isolates, Acinetobacter spp. was the most common pathogen 21(44.7%) followed by Pseudomonas aeruginosa 11(23.4%), Klebsiella pneumoniae 10(21.3%), Escherichia coli 4(8.5%) and Citrobacter freundii 1(2.1%). Highest number of AECOPD cases were observed in female 157(57.9%) with 25(15.9%) positivity and highest number of organisms were isolated in age group 56-70(17) and least in age group 40-55(3).
All the Acinetobacter spp. (n=21) isolates were resistant to all tested medicine. Almost 90.90% Pseudomonas aeruginosa (n=11) were sensitive to Gentamycin and 81.82% to Meropenem, 70% Klebsiella pneumoniae (n=10) were sensitive to Gentamycin, 75% Escherichia coli (n=4) and 100 % Citrobacter freundii (n=1) to Amikacin. 100% (n=47) isolates were resistant to antibiotic penicillin and 100% Escherichia coli and Citrobacter freundii were resistance to Ceftriazone and Cefepime while 100% (n=47) were found to be multi-drug resistant.
Conclusion Acinetobacter spp P. aeruginosa, Klebsiella pneumoniae, and Escherichia coli were the most common bacterial isolates in the current investigation, which revealed a 15.4 % of culture positive. There is a high rate of MDR pattern in all isolated isolates. To further enhance treatment quality and prevent antibiotic resistance, regular surveillance of the etiologies of AECOPD and their pattern of antimicrobial susceptibility is crucial.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee of Shree Birendra Hospital (NAIHS-IRC), Chhauni, Kathmandu, gave ethical approval for this work on Sep 10, 2023.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors. If all data are included in the manuscript, you can alternatively use: All data produced in the present work are contained in the manuscript. Choose the one that best fits your data-sharing approach.
